Cytotoxic chemotherapy for differentiated thyroid carcinoma.
For patients with metastatic differentiated thyroid carcinoma that progresses despite standard therapies, systemic cytotoxic chemotherapy has traditionally been a limited option. Historically, phase II studies and small retrospective series have failed to identify highly effective drugs or regimens, in part by failing to recruit sufficient numbers of patients. Doxorubicin remains the single most effective cytotoxic chemotherapy for the treatment of metastatic disease, although complete responses are rare, partial responses limited and toxicity considerable. Newer agents, such as pemetrexed, may be of benefit and potentially better tolerated. Newer approaches to treatment as well as trial design and recruitment, emphasising the role of thyroid cancer patients in early drug trials, may yield advances in patient benefit.[1]References
- Cytotoxic chemotherapy for differentiated thyroid carcinoma. Sherman, S.I. Clin. Oncol. (R. Coll. Radiol) (2010) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
